Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
Rhea-AI Summary
Prenetics (NASDAQ: PRE) announced that CEO Danny Yeung and CFO Brian Rosin purchased a combined $1.0 million of ordinary shares in the open market between August 20–25, 2026, within the post‑earnings trading window. Leadership has now cumulatively invested about $3.75 million in company shares since November 2025, with no sales reported.
Yeung bought 24,681 shares for roughly $502,000 and now totals about $1.75 million of personal purchases. Rosin acquired 23,100 shares for roughly $498,000 in his first open‑market buy.
According to Prenetics, Q2 2026 revenue reached $46.5 million, up ~288% year over year, including $45.0 million from IM8, up ~359%. IM8 generated $20.9 million revenue in July, implying a ~$251 million annualized run‑rate, and the company recorded its first month of positive consolidated Adjusted Free Cash Flow, a non‑IFRS metric. Prenetics raised 2026 revenue guidance to $220–230 million and issued 2027 guidance of more than $400 million. Management also highlighted a $1 billion growth financing commitment to IM8 from General Catalyst's Customer Value Fund.
Positive
- Insider open-market buying $1.0 million by CEO and CFO in August 2026
- Leadership cumulative investment approximately $3.75 million since November 2025 with no sales
- Q2 2026 revenue $46.5 million, approximately 288% year-over-year growth
- IM8 Q2 2026 revenue $45.0 million, approximately 359% year-over-year growth
- IM8 July 2026 revenue $20.9 million, ~$251 million annualized run-rate
- First month of positive consolidated Adjusted Free Cash Flow in July 2026 (non-IFRS)
- Raised 2026 revenue guidance to $220–230 million
- Introduced 2027 revenue guidance of more than $400 million
- General Catalyst Customer Value Fund $1 billion growth financing commitment to IM8
Negative
- None.
News Explained
Prenetics’ July positive Adjusted Free Cash Flow was defined as net cash from operating activities plus net fundings under the General Catalyst Customer Value Fund facility, so it is a non-IFRS measure rather than a standardized operating-cash figure.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 20 | Ambassador partnership | Positive | -4.2% | Lily Collins became IM8 ambassador and shareholder in a multi-year partnership. |
| Aug 18 | Q2 earnings report | Positive | +0.1% | Q2 revenue grew 288% year over year and guidance increased. |
| Aug 17 | Preferred dividend declaration | Neutral | +0.1% | MetLife declared third-quarter preferred stock dividends across four series. |
| Aug 17 | Independent director appointment | Positive | -1.9% | Caroline Levy joined the board and three board committees. |
| Aug 07 | Earnings date announcement | Neutral | +2.2% | Prenetics scheduled Q2 results and announced upcoming investor conference participation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent PRE announcements produced mixed reactions, with two positive reactions and two negative reactions among comparable company news.
Key Terms
open market purchases financial
adjusted free cash flow financial
annualized revenue run-rate financial
non-ifrs financial measure financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately
NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham, today announced that Danny Yeung, Chief Executive Officer, and Brian Rosin, Chief Financial Officer, completed open market purchases of the Company’s ordinary shares during the period between August 20 and August 25, 2026, within the Company’s open trading window following the release of second quarter 2026 financial results.
The two executives acquired
Individual Transaction Details
Danny Yeung, Chief Executive Officer
Purchased 24,681 shares for approximately
Brian Rosin, Chief Financial Officer
Purchased 23,100 shares for approximately
Purchases Follow Second Quarter Results
On August 18, 2026, Prenetics reported total second quarter revenue of
Management Commentary
Danny Yeung, Chief Executive Officer of Prenetics, stated: “This is my third open market purchase since November, and the reason has not changed — the business has only gotten stronger. The clearest validation came in July, when General Catalyst's Customer Value Fund committed
Brian Rosin, Chief Financial Officer, added: “I have spent my career in consumer health and have seen plenty of good brands, but what drew me to IM8 was a set of special characteristics I had not seen combined anywhere else. Three months inside Prenetics, the detail has only confirmed those traits run deeper than I thought. Capital allocation is the core of my job, and I’m applying that same discipline to my own capital and buying in my first available window.”
About Prenetics
Prenetics Global Limited (NASDAQ: PRE) is a leading consumer health company on a mission to advance human health and longevity. Its flagship brand, IM8, co-founded with David Beckham, is redefining premium daily nutrition through science-backed formulations — anchored by Daily Ultimate Essentials, a 90-ingredient daily nutrition system that is NSF Certified for Sport and clinically studied. IM8 is the fastest-growing premium supplement brand ever recorded, reaching approximately
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com. Follow IM8 on Instagram at @im8health for updates.
Investor Relations Contact
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance reflects management’s current estimates and assumptions as of the date of this press release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the impact of the Customer Investment Agreement with GC Customer Value Arranger, LLC is unpredictable, and the arrangement may not function as expected, and its failure to do so could materially and adversely impact our financial condition and results of operations, we may require additional capital to grow our business, which may not be available on terms acceptable to us or at all, the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers’ expectations; the Company’s ability to further develop and grow its business, including new products and services; and the Company’s ability to efficiently and effectively deploy financial and management resources towards maintaining and growing the business. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law. Nothing in this press release constitutes an offer to sell, or the solicitation of an offer to buy, any securities of the Company.
Unaudited Non-IFRS Financial Measures
The Company is providing the following non-IFRS measure: Adjusted Free Cash Flow. This non-IFRS financial measure is not based on any standardized methodology prescribed by IFRS and is not necessarily comparable to similarly-titled measures presented by other companies. Management believes this non-IFRS financial measure is useful to investors in evaluating the Company’s ongoing operating results and trends and in facilitating period-to-period comparisons of the Company’s performance. Adjusted Free Cash Flow, a non-IFRS measure, is defined as net cash from operating activities plus net fundings under the General Catalyst Customer Value Fund facility. Other companies, including companies in the same industry, may not use the same non-IFRS measure or may calculate this metric in a different manner than management, or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of this non-IFRS measure as a comparative measure. Because of these limitations, the Company’s non-IFRS financial measure should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS Accounting Standards.
